Jiaotong University on December 18, 2021. It is expected to be completed in the first quarter of 2022. The purpose of the trial is to compare the drug metabolism of YG1699 between Chinese and American races, prove the racial differences between Americans and Chinese, and provide data for future intermnational multi center clinical research and Chinese clinical application for approval.

YG1699 is the leading product of Yougene. The company has independent intellectual property rights and is carrying out phase II clinical trials in the United States. It is reported that, This product is the world's leading SGLT2 inhibitor in addition to retaining the urinary glucose excretion channel of SGLT2 inhibitor, in the drug molecular design, the iterative product of (Liejing products) specially introduces the inhibitory activity of SGLT1 and opens up a unique intestinal glucose excretion channel, so that YG1699 product can obtain two hypoglycemic channels in the kidney and intestine at the same time. It can not only directly excrete the elevated blood glucose from the urine like engliejing, but also prevent Glucose in food is absorbed into the blood, directly from the intestine and excreted through fecal metabolism. In addition, the completed phase I clinical study data in the United States showed that YG1699's treatment can significantly increase the secretion level of natural GLP-1 in the body, The effect is similar to that of oral GLP-1 receptor agonists (e.g. Novo Nordisk rybelsus) (oral somaluptide). Due to the unique biological mechanism of the product, the company plans to carry out clinical research on the product in many fields of metabolic diseases. Through this research, Youngene hopes to promote more American clinical data to Chinese patients, so as to speed up the application and listing of the drug in China.

About Youngene

Youngene Therapeutics Co., Ltd. is a new drug R&D company with clinical phase II products focusing on metabolic diseases. At present, several R&D pipelines have been established. YG1699 completed phase I in the United States. Phase II of type 1 diabetes is being carried out in the United States. It is expected that all patients will be enrolled in the first quarter of 2022. In addition, the company has a number of products in the preclinical development stage.